VEGFR-3 / Flt-4 (His-tagged) Human Protein
VEGFR-3 / Flt-4 (His-tagged) human recombinant protein, 10 µg
|Description||VEGFR-3 / Flt-4 (His-tagged) human recombinant protein, 10 µg|
|Predicted MW||120 kDa|
|Purity||>90% by SDS-PAGE and visualised by silver stain|
|Buffer||Presentation State: Purified
State: Lyophilized without buffer and stabilizer.
|Bioactivity||Biological: Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay.
Immobilised recombinant human sVEGFR-3/FLT-4 at 5 µg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.
|Endotoxin||< 0.1 ng per µg of sVEGFR-3|
|Reconstitution||Restore in PBS or medium to a concentration not lower than 100 µg/ml.|
|Preparation||Lyophilized without buffer and stabilizer.|
|Protein Description||The recombinant mature sVEGFR-3/FLT-4 is a glycosylated monomeric protein with a mass of approximately 120 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Glu774).|
|Note||Centrifuge vials before opening!|
|Storage||Prior to and following reconstitution store the antibody at -20°C.
Avoid repeated freezing and thawing.
|Stability||Shelf life: one year from despatch.|
|Synonyms||FLT-4; FLT41; LMPH1A; LMPHM1; PCL; VEGFR-3; VEGFR3|
|Summary||This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA. [provided by RefSeq, Jul 2008]|
|Protein Families||Druggable Genome, Protein Kinase, Transmembrane|
|Protein Pathways||Cytokine-cytokine receptor interaction, Focal adhesion|